{"id":4709,"date":"2025-03-31T18:12:17","date_gmt":"2025-03-31T18:12:17","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/tenofovir-disoproxil-txt\/"},"modified":"2025-03-31T18:12:17","modified_gmt":"2025-03-31T18:12:17","slug":"tenofovir-disoproxil-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/tenofovir-disoproxil-txt\/","title":{"rendered":"tenofovir disoproxil.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nNucleoside reverse transcriptase inhibitor:Treatment of HIV in combination with other antiretroviral drugsTreatment of hepatitis B in compensated liver disease

DOSE IN NORMAL RENAL FUNCTION <\/H3>245 mg once daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :635.5 (as disoproxil fumarate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0.7\u20137.2<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : IV: 70\u201380; Oral: 32<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.8<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :12\u201318\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 245 mg every 48 hours10\u201330 245 mg every 72\u201396 hours
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 245 mg every 7 days

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antivirals: reduces concentration of atazanavir; concentration of both drugs may be increased with cidofovir; increased didanosine concentration resulting in increased toxicity (e.g. pancreatitis and lactic acidosis) \u2013 avoid concomitant use; concentration increased by lopinavir and atazanavir; monitor renal function with adefovirCo-administration with other drugs that are actively secreted via the tubular anionic transporter, e.g. cidofovir \u2013 increased concentrations of both drugs

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Lactic acidosis, sometimes fatal, and usually associated with severe hepatomegaly and steatosis, has been reported in patients receiving nucleoside reverse transcriptase inhibitorsFollowing a single 300 mg dose of tenofovir, subjects with a calculated creatinine clearance <50 mL\/min, and those with ERF requiring dialysis, had substantial reductions in renal elimination of tenofovir, resulting in high systemic exposures necessitating an adjustment in doseA 4 hour high-flux haemodialysis session was found to remove 10% of tenofovir from plasmaRenal impairment, which may include hypophosphataemia, has been reported with the use of tenofovir. The majority of these cases occurred in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents \u2013 monitor creatinine clearance and phosphate levels
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Nucleoside reverse transcriptase inhibitor:Treatment of HIV in combination<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4709","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4709"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4709\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}